Benoit I. Giasson
#160,438
Most Influential Person Now
Benoit I. Giasson's AcademicInfluence.com Rankings
Benoit I. Giassonbiology Degrees
Biology
#12674
World Rank
#16165
Historical Rank
Neuroscience
#2141
World Rank
#2201
Historical Rank
Biochemistry
#2178
World Rank
#2323
Historical Rank
Download Badge
Biology
Benoit I. Giasson's Degrees
- PhD Neuroscience Université de Montréal
- Masters Biology Université de Montréal
- Bachelors Biochemistry Université de Montréal
Similar Degrees You Can Earn
Why Is Benoit I. Giasson Influential?
(Suggest an Edit or Addition)Benoit I. Giasson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. (2000) (1546)
- Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein (2002) (974)
- A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* (2001) (882)
- Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein (2003) (802)
- Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * (1999) (534)
- Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. (2002) (530)
- Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. (2000) (529)
- Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult (2001) (369)
- A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. (2013) (357)
- Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. (2013) (347)
- The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* (2005) (323)
- Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases (2002) (318)
- Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† (2003) (296)
- Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies (2002) (283)
- Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration (2005) (271)
- Up‐Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn‐Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis (1999) (267)
- DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function (2010) (266)
- The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. (2002) (265)
- Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* (2005) (261)
- Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. (2000) (257)
- Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice (2014) (254)
- Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. (2004) (244)
- Concurrence of α-synuclein and tau brain pathology in the Contursi kindred (2002) (243)
- Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. (2010) (237)
- Chaperone‐like activity of synucleins (2000) (236)
- Are Ubiquitination Pathways Central to Parkinson's Disease? (2003) (219)
- Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. (2002) (216)
- Glucocerebrosidase mutations are an important risk factor for Lewy body disorders (2006) (214)
- α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia (2008) (213)
- Induction of alpha-synuclein aggregation by intracellular nitrative insult. (2001) (211)
- A Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation (2005) (211)
- Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein (2008) (202)
- Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. (2000) (200)
- Nitration of tau protein is linked to neurodegeneration in tauopathies. (2003) (197)
- Alpha-synuclein: normal function and role in neurodegenerative diseases. (2004) (197)
- Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease (2001) (188)
- Molecular mechanisms of alpha-synuclein neurodegeneration. (2009) (182)
- Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. (2003) (181)
- More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases (2004) (178)
- Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies (2015) (171)
- Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders (2010) (171)
- Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* (2003) (168)
- The E46K mutation in alpha-synuclein increases amyloid fibril formation. (2005) (168)
- Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau (2011) (162)
- Parkin and the Molecular Pathways of Parkinson's Disease (2001) (161)
- Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* (2003) (155)
- Cytosolic Catechols Inhibit α-Synuclein Aggregation and Facilitate the Formation of Intracellular Soluble Oligomeric Intermediates (2006) (154)
- Alpha‐synuclein and its disease‐causing mutants induce ICAM‐1 and IL‐6 in human astrocytes and astrocytoma cells (2006) (150)
- A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. (2005) (150)
- A cellular system that degrades misfolded proteins and protects against neurodegeneration. (2014) (147)
- Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation (2004) (138)
- Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. (2002) (137)
- γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways* (2002) (137)
- MAPT mutations, tauopathy, and mechanisms of neurodegeneration (2019) (135)
- Snaring the Function of α-Synuclein (2005) (134)
- Aberrant Stress-induced Phosphorylation of Perikaryal Neurofilaments* (1996) (133)
- Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies (2003) (128)
- Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous α-Synuclein Inclusions of α-Synucleinopathies (2006) (124)
- Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model (2007) (118)
- E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment* (2011) (117)
- Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits. (2013) (115)
- Brain Injection of α-Synuclein Induces Multiple Proteinopathies, Gliosis, and a Neuronal Injury Marker (2014) (114)
- Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α‐synuclein (2014) (111)
- A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114 (2003) (110)
- Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice (2014) (109)
- Age-dependent synuclein pathology following traumatic brain injury in mice (2003) (108)
- Degradative organelles containing mislocalized α- and β-synuclein proliferate in presenilin-1 null neurons (2004) (105)
- Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. (2006) (99)
- Cleavage of α-Synuclein by Calpain: Potential Role in Degradation of Fibrillized and Nitrated Species of α-Synuclein† (2005) (98)
- Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. (2004) (98)
- Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. (2009) (97)
- Distinct Region-Specific α-Synuclein Oligomers in A53T Transgenic Mice: Implications for Neurodegeneration (2010) (96)
- Interactions of amyloidogenic proteins (2007) (95)
- Thinking laterally about neurodegenerative proteinopathies. (2013) (93)
- Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. (1998) (91)
- α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease (2019) (84)
- Characterization of antibodies that selectively detect α-synuclein in pathological inclusions (2008) (83)
- Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. (2009) (82)
- LRRK2 phosphorylates novel tau epitopes and promotes tauopathy (2013) (82)
- A novel, high‐efficiency cellular model of fibrillar α‐synuclein inclusions and the examination of mutations that inhibit amyloid formation (2010) (82)
- Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein (2013) (82)
- Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. (2014) (81)
- A new link between pesticides and Parkinson's disease (2000) (79)
- Neurofurans, Novel Indices of Oxidant Stress Derived from Docosahexaenoic Acid* (2008) (78)
- SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice (2018) (76)
- The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. (2001) (76)
- Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. (2003) (76)
- Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. (2003) (75)
- Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. (2005) (74)
- Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. (2007) (73)
- DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein (2005) (72)
- Characterization of kinases involved in the phosphorylation of aggregated α‐synuclein (2011) (72)
- Snaring the function of alpha-synuclein. (2005) (69)
- Conformational templating of α-synuclein aggregates in neuronal-glial cultures (2013) (68)
- Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils (2016) (63)
- The environmental toxin arsenite induces tau hyperphosphorylation. (2002) (62)
- Dityrosine cross-linking promotes formation of stable α-synuclein polymers (2000) (59)
- The emerging role of α-synuclein truncation in aggregation and disease (2020) (59)
- Evidence of Native α-Synuclein Conformers in the Human Brain* (2014) (58)
- Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. (2005) (57)
- Prion-like Spreading in Tauopathies (2018) (55)
- Clinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations (2009) (54)
- Proteolysis of α‐synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology (2017) (52)
- Mutations in LRRK2 as a Cause of Parkinson’s Disease (2007) (51)
- The targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue (2017) (51)
- Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies (2017) (50)
- Expression of α-, β-, and γ-synuclein in glial tumors and medulloblastomas (2003) (47)
- Prominent Perikaryal Expression of α- and β-Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons (2001) (47)
- Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions (2018) (46)
- Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity (2017) (46)
- Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential (2021) (45)
- Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes (2016) (45)
- Activation of Stress‐Activated Protein Kinases Correlates with Neurite Outgrowth Induced by Protease Inhibition in PC12 Cells (1999) (44)
- Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants (2012) (42)
- Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. (2003) (42)
- A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies (2017) (39)
- Determinants of seeding and spreading of α-synuclein pathology in the brain (2020) (39)
- Propagation of Aβ, tau and α-synuclein pathology between experimental models and human reality: prions, propagons and propaganda (2015) (39)
- TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease (2018) (39)
- Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. (2018) (39)
- “Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies (2021) (38)
- Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions (2013) (37)
- Endogenous Oligodendroglial Alpha-Synuclein and TPPP/p25α Orchestrate Alpha-Synuclein Pathology in Experimental Multiple System Atrophy Models (2019) (37)
- Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice (2017) (37)
- Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau (2017) (36)
- α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. (2011) (34)
- Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies (2020) (33)
- Cp/Heph mutant mice have iron‐induced neurodegeneration diminished by deferiprone (2015) (32)
- DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity. (2010) (32)
- Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression (2019) (32)
- Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice (2015) (31)
- rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies (2019) (30)
- The E163K DJ-1 mutant shows specific antioxidant deficiency (2008) (29)
- Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With &agr;-Synuclein Inclusions (2009) (29)
- Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils (2019) (28)
- Precision therapeutic targets for COVID-19 (2021) (28)
- Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. (2001) (27)
- Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts (2018) (25)
- Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy (2013) (25)
- The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture (2015) (24)
- Developmentally regulated stabilization of neuronal intermediate filaments in rat cerebral cortex (1997) (23)
- The E 46 K Mutation in-Synuclein Increases Amyloid Fibril Formation * (2005) (23)
- Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease (2018) (23)
- Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course. (2017) (23)
- Comparison of the in vivo induction and transmission of &agr;-synuclein pathology by mutant &agr;-synuclein fibril seeds in transgenic mice (2017) (22)
- Role of Mitochondrial Dysfunction in Parkinson’s Disease (2007) (22)
- Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology (2015) (20)
- Physiologically relevant factors influence tau phosphorylation by leucine‐rich repeat kinase 2 (2015) (19)
- Phosphorylation of serine 305 in tau inhibits aggregation (2019) (18)
- Okadaic acid reversibly inhibits neurite outgrowth in embryonic dorsal root ganglion neurons. (1997) (17)
- The major targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue (2017) (16)
- Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation. (2010) (16)
- Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. (2019) (16)
- Differential cross-seeding properties of tau and α-synuclein in mouse models of tauopathy and synucleinopathy (2020) (15)
- Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes (2020) (15)
- Locomotor differences in mice expressing wild-type human α-synuclein (2018) (15)
- Functional Consequences of α-Synuclein Tyrosine Nitration (2004) (15)
- Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis (2019) (14)
- Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions (2021) (13)
- Carboxy‐terminal truncations of mouse α‐synuclein alter aggregation and prion‐like seeding (2020) (13)
- Impaired tau–microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations (2019) (13)
- The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome (2017) (13)
- Transgenic mice expressing S129 phosphorylation mutations in α-synuclein (2014) (13)
- Novel monoclonal antibodies targeting the microtubule-binding domain of human tau (2018) (12)
- Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease (2020) (11)
- Mitochondrial injury: a hot spot for parkinsonism and Parkinson's disease? (2004) (9)
- Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier – phenotypic variability in autosomal dominant Alzheimer’s disease (2020) (9)
- Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis (2018) (9)
- Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy (2020) (9)
- Increased phosphorylation of neurofilament subunits in PC12 cells and rat dorsal root ganglion neurons treated with N-Acetyl-Leu-Leu-norleucinal (1995) (9)
- Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau–microtubule interactions and inhibits aggregation (2021) (8)
- Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission (2015) (8)
- Robust α-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy (2021) (8)
- α-Synuclein Induces Progressive Changes in Brain Microstructure and Sensory-Evoked Brain Function That Precedes Locomotor Decline (2020) (8)
- An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes (2019) (7)
- Il-10 signaling reduces survival in mouse models of synucleinopathy (2021) (7)
- Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? (2012) (7)
- Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice (2022) (7)
- Studies of protein aggregation in A53T α-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice (2012) (6)
- Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model (2021) (6)
- Common threads in neurodegenerative disorders of aging (2006) (6)
- Adsorption and decontamination of α-synuclein from medically and environmentally-relevant surfaces. (2018) (6)
- α-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability (2021) (6)
- Mutations in LRRK 2 as a Cause of Parkinson ’ s Disease (2007) (6)
- Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases. (2020) (6)
- Fragile X-associated tremor ataxia syndrome with co-occurrent progressive supranuclear palsy-like neuropathology (2019) (6)
- Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies (2021) (6)
- Pathogenic MAPT mutations Q336H and Q336R have isoform‐dependent differences in aggregation propensity and microtubule dysfunction (2021) (5)
- Exploring the Peripheral Initiation of Parkinson’s Disease in Animal Models (2019) (4)
- Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology (2018) (4)
- Animal models of neurodegenerative dementing disorders other than Alzheimer's disease (2004) (4)
- Combinatorial model of amyloid β and tau reveals synergy between amyloid deposits and tangle formation (2021) (4)
- Biochemistry of neurodegeneration [2] (multiple letters) (2001) (3)
- Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy (2021) (3)
- Corrigendum to “Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2” [Biochem. Biophys. Res. Commun. 378 (2009) 473–477] (2009) (3)
- Tau and α-Synuclein in Neurodegenerative Diseases (2001) (3)
- Conformational templating of α-synuclein aggregates in neuronal-glial cultures (2013) (3)
- Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology (2022) (3)
- The Neuropathology of Dementia: Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with α-synuclein inclusions (2004) (3)
- Novel monoclonal antibodies targeting the RRM2 domain of human TDP-43 protein (2020) (3)
- Prion-like transmission of α-synuclein pathology in the context of an NFL null background (2017) (2)
- Targeted proteolytic products of τ and α-synuclein in neurodegeneration (2021) (2)
- Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts. (2021) (1)
- Impact of APOE genotype on prion-type propagation of tauopathy (2022) (1)
- Exploring the pathologic synergy between amyloid β and tau (2020) (1)
- Erratum to: Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice (2014) (1)
- Designing antibodies against LRRK2-targeted tau epitopes (2018) (1)
- Mechanisms of oxidative damage in neurodegenerative synucleinopathies (2000) (1)
- Tauopathy Mouse Models (2015) (1)
- Correction to: Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models (2019) (1)
- Novel SOD1 monoclonal antibodies against the electrostatic loop preferentially detect misfolded SOD1 aggregates (2020) (1)
- Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein (2013) (1)
- The neuropathology of neurodegeneration with brain iron accumulation, type 1 (NBIA 1) contains insoluble α-synuclean (2000) (0)
- Optical pulse labeling studies reveal exogenous seeding slows α-synuclein clearance (2022) (0)
- Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice (2022) (0)
- Robust α-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy (2021) (0)
- “Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies (2021) (0)
- MODELING TAUOPATHY USING AAV-MEDIATED SOMATIC BRAIN TRANSGENESIS (2018) (0)
- MhcII Regulates Transmission of α-Synuclein-Seeded Pathology in Mice (2022) (0)
- Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes (2016) (0)
- Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology (2018) (0)
- TARGETING TAU AGGREGATION IN BRAIN SLICE CULTURE MODELS OF TAUOPATHIES (2017) (0)
- Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies (2020) (0)
- 108 Mutant glucocerebrosidase and the synucleinopathies (2007) (0)
- Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice (2015) (0)
- Targeting aggregated tau turnover as a therapeutic strategy (2021) (0)
- Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier – phenotypic variability in autosomal dominant Alzheimer’s disease (2020) (0)
- Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau (2017) (0)
- Cell-to-cell transmission of synucleinopathy (2015) (0)
- Correction to: Prodromal neuroinvasion of pathological α-synuclein in brainstem reticular nuclei and white matter lesions in a model of α-synucleinopathy (2022) (0)
- Precision therapeutic targets for COVID-19 (2021) (0)
- Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice (2017) (0)
- 34. The contribution of lysosomal pathways to the pathogenesis of common neurodegenerative disorders: Glucocerebrosidase and the synucleinopathies (2008) (0)
- α-Synuclein nitration in neuropathological inclusions (2000) (0)
- Impact of APOE genotype on prion-type propagation of tauopathy (2022) (0)
- Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity (2017) (0)
- Tau Lysine Pseudomethylation Regulates Microtubule Binding and Enhances Prion-like Tau Aggregation (2023) (0)
- Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils (2019) (0)
- COMPARATIVE PRIONOID AND STRAIN PROPERTIES OF TAU AND SYNUCLEIN (2019) (0)
- Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression (2019) (0)
- Robust CNS pathology in transgenic mice following peripheral injection of α-synuclein 1 fibrils 2 3 Running title : Peripheral routes of α-synuclein injection 4 5 (2016) (0)
- Corrigendum to “Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy” [Neurosci. Lett. 732 (2020) 1–11/135017] (2022) (0)
- Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy (2022) (0)
- IL-10 modifies disease progression and pathology in a mouse model of alpha synucleinopathy (2015) (0)
- Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model (2021) (0)
- Novel insights in the pathophysiology of α-synuclein dysregulation on D2 receptor activity contributing to the vulnerability of dopamine neurons (2021) (0)
- FROM SYSTEMS LEVEL TRANSCRIPTOMICS TO NEW IMMUNE TARGETS FOR ALZHEIMER’S DISEASE (2016) (0)
- Il-10 signaling reduces survival in mouse models of synucleinopathy (2021) (0)
- Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology (2022) (0)
- Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? (2012) (0)
- P1-302 Implications of dopamine-induced modificationsof alpha-synuclein protein in the pathogenesis of Parkinson's disease (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Benoit I. Giasson?
Benoit I. Giasson is affiliated with the following schools:
